← Back to Screener
Zymeworks Inc. (ZYME)
Price$27.85
Favorite Metrics
Price vs S&P 500 (26W)45.18%
Price vs S&P 500 (4W)9.72%
Market Capitalization$1.98B
All Metrics
Book Value / Share (Quarterly)$3.57
P/TBV (Annual)7.43x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-36.43%
Cash Flow / Share (Quarterly)$-0.47
Price vs S&P 500 (YTD)1.44%
Net Profit Margin (TTM)-74.18%
EPS (TTM)$-1.08
10-Day Avg Trading Volume0.57M
EPS Excl Extra (TTM)$-1.08
Revenue Growth (5Y)22.13%
EPS (Annual)$-1.08
ROI (Annual)-30.22%
Net Profit Margin (5Y Avg)-231.32%
Cash / Share (Quarterly)$3.04
Revenue Growth QoQ (YoY)-91.90%
ROA (Last FY)-23.41%
Revenue Growth TTM (YoY)3.34%
EBITD / Share (TTM)$-1.17
ROE (5Y Avg)-30.36%
Operating Margin (TTM)-84.88%
Cash Flow / Share (Annual)$-0.47
P/B Ratio7.37x
P/B Ratio (Quarterly)7.39x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)24.58x
Net Interest Coverage (TTM)-96.25x
ROA (TTM)-20.57%
EV / EBITDA (TTM)9.14x
EPS Incl Extra (Annual)$-1.08
Current Ratio (Annual)5.88x
Quick Ratio (Quarterly)5.52x
3-Month Avg Trading Volume0.71M
52-Week Price Return147.11%
EV / Free Cash Flow (Annual)0.77x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.55
P/S Ratio (Annual)18.68x
Asset Turnover (Annual)0.31x
52-Week High$28.49
Operating Margin (5Y Avg)-244.90%
EPS Excl Extra (Annual)$-1.08
CapEx CAGR (5Y)-17.89%
Tangible BV CAGR (5Y)-7.14%
26-Week Price Return53.93%
Quick Ratio (Annual)5.52x
13-Week Price Return12.92%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)5.88x
Enterprise Value$1,938.54
Revenue / Share Growth (5Y)12.68%
Asset Turnover (TTM)0.21x
Book Value / Share Growth (5Y)-16.71%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-75.26%
Cash / Share (Annual)$3.04
3-Month Return Std Dev39.91%
Net Income / Employee (TTM)$-0
ROE (Last FY)-30.22%
Net Interest Coverage (Annual)-726.00x
EPS Basic Excl Extra (Annual)$-1.08
P/FCF (TTM)176.93x
Receivables Turnover (TTM)2.61x
EV / Free Cash Flow (TTM)1.36x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.08
Receivables Turnover (Annual)3.51x
ROI (TTM)-26.00%
P/S Ratio (TTM)25.11x
Pretax Margin (5Y Avg)-229.54%
Revenue / Share (Annual)$1.41
Tangible BV / Share (Annual)$3.55
Price vs S&P 500 (52W)112.02%
Year-to-Date Return5.58%
5-Day Price Return6.23%
EPS Normalized (Annual)$-1.08
ROA (5Y Avg)-21.12%
Net Profit Margin (Annual)-76.56%
Month-to-Date Return11.02%
Cash Flow / Share (TTM)$3.17
EBITD / Share (Annual)$-1.18
Operating Margin (Annual)-87.34%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-30.35%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.08
P/TBV (Quarterly)7.43x
P/B Ratio (Annual)7.39x
Pretax Margin (TTM)-73.06%
Book Value / Share (Annual)$3.57
Price vs S&P 500 (13W)10.05%
Beta1.21x
P/FCF (Annual)15.11x
Revenue / Share (TTM)$1.05
ROE (TTM)-26.00%
52-Week Low$10.69
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.25
4.25
4.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ZYMEZymeworks Inc. | 25.11x | 3.34% | — | — | $27.85 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Zymeworks is a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics using its proprietary drug development platform. Its lead candidate, zanidatamab, is a HER2-targeted bispecific antibody currently in Phase 1/2 and pivotal clinical trials for solid tumors expressing HER2. The company also maintains a preclinical pipeline in oncology and other therapeutic areas.